Phase 1 exploratory trial in Diffuse Cutaneous Systemic Sclerosis
Latest Information Update: 10 Aug 2021
At a glance
- Drugs Teprotumumab (Primary)
- Indications Diffuse scleroderma
- Focus Adverse reactions
Most Recent Events
- 04 Aug 2021 According to a Horizon Therapeutics media release, this trial is expected to initiate in third quarter of 2021
- 09 May 2021 New trial record
- 05 May 2021 According to a Horizon Therapeutics media release, this trial is expected to initiate in mid-2021.